P&K Skin Research Center

피엔케이피부임상연구센타 · 347740

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$41.9M (₩57.8B)

Overview

P&K Skin Research Center runs a clinical testing laboratory that measures whether cosmetics, beauty devices, and health supplements actually do what their makers claim, running both human-subject trials and lab-based tests.

Its clients are domestic and international manufacturers and distributors of cosmetics, beauty devices, and health functional foods. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the large majority of its revenue from cosmetic human-application trials, with other human trials and lab tests making up the remainder.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$16.5M
▲ +27.7% YoY
Operating profit · FY2025
US$2.9M
▲ +52.6% YoY
Net income · FY2025
US$3.3M
▼ −19.2% YoY

Revenue

  • FY2023US$10.8M
  • FY2024US$12.9M
  • FY2025US$16.5M

Operating profit

  • FY2023US$999.2K
  • FY2024US$1.9M
  • FY2025US$2.9M

Net income

  • FY2023US$3.4M
  • FY2024US$4.1M
  • FY2025US$3.3M

Key ratios (FY2025)

ROE
5.7%
Debt/Eq
7.5%
Op. margin
17.3%
Net margin
20.2%
Rev. YoY
▲ +27.7%

Why it matters

Korean regulations require cosmetics makers to obtain certified efficacy evidence from the Ministry of Food and Drug Safety before making functional claims, which underpins demand for third-party testing services like those P&K provides.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.